

# 1 Anti-Spike protein assays to determine 2 post-vaccination antibody levels: a 3 head-to-head comparison of five 4 quantitative assays

5 Running head: Comparison of five quantitative SARS-CoV-2 antibody assays after  
6 vaccination

7 Thomas Perkmann<sup>1</sup>, Nicole Perkmann-Nagele<sup>1</sup>, Thomas Koller<sup>1</sup>, Patrick Mucher<sup>1</sup>, Astrid  
8 Radakovics<sup>1</sup>, Rodrig Marculescu<sup>1</sup>, Michael Wolzt<sup>2</sup>, Oswald F. Wagner<sup>1</sup>, Christoph J. Binder<sup>1</sup>,  
9 Helmuth Haslacher<sup>1</sup>

10

11 <sup>1</sup>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

12 <sup>2</sup>Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

13 Correspondence to:

14 Helmuth HASLACHER, LECT MD PhD BSc

15 Medical University of Vienna

16 Department of Laboratory Medicine

17 Waehringer Guertel 18-20, 1090 Vienna, Austria

18 Phone: +43 1 40400 53190

19 Fax: +43 1 40495 15547

20 Mail: [helmuth.haslacher@meduniwien.ac.at](mailto:helmuth.haslacher@meduniwien.ac.at)

## 21 Abstract (239/250)

### 22 Background

23 Reliable quantification of the antibody response to SARS-CoV-2 vaccination is highly relevant  
24 for identifying possible vaccine failure and estimating the time of protection. Therefore, we  
25 aimed to evaluate the performance of five different Anti-SARS-CoV-2 antibody assays regarding  
26 the quantification of anti-spike (S) antibodies induced after a single dose of BNT162b2.

### 27 Methods

28 Sera of n=69 SARS-CoV-2 naïve individuals  $21 \pm 1$  days after vaccination with BNT162b2  
29 (Pfizer/BioNTech) were tested using the following quantitative SARS-CoV-2 antibody assays:  
30 Roche S total antibody, DiaSorin trimeric spike IgG, DiaSorin S1/S2 IgG, Abbott II IgG, and  
31 Serion/Virion IgG. Test agreement was assessed by Passing-Bablok regression. Results were  
32 further compared to the percent inhibition calculated from a surrogate virus neutralization test  
33 (sVNT) by correlation and ROC (receiver-operating-characteristics) analysis.

### 34 Results

35 Individual values were distributed over several orders of magnitude for all assays evaluated.  
36 Although the assays were in good overall agreement ( $\rho=0.80-0.94$ ), Passing-Bablok regression  
37 revealed systematic and proportional differences, which could not be eliminated by converting  
38 the results to BAU/mL as suggested by the manufacturers. 7 (10%) individuals had a negative  
39 sVNT results (i.e. <30% inhibition). These samples were reliably identified by most assays and  
40 yielded low binding antibody levels (ROC-AUCs 0.84-0.93).

## 41 Conclusions

42 Although all assays evaluated showed good correlation, readings from different assays were not  
43 interchangeable, even when converted to BAU/mL using the WHO international standard for  
44 SARS-CoV-2 immunoglobulin. This highlights the need for further standardization of SARS-  
45 CoV-2 serology.

46 **Keywords: SARS-CoV-2; serology; vaccination; BNT162b2; antibody testing**

## 47 Abbreviations

48	SARS-CoV-2	Severe acute respiratory syndrome Coronavirus 2
49	COVID-19	Coronavirus Disease 19
50	NC	Nucleocapsid
51	S	Spike protein
52	tAb	total antibody
53	ECLIA	electrochemiluminescence immunoassay
54	RBD	receptor binding domain
55	CMIA	chemiluminescence microparticle assay
56	CLIA	chemiluminescence immunoassay
57	ELISA	enzyme-linked immunosorbent assay
58	BAU/MI	binding antibody units per milliliter
59	sVNT	surrogate virus neutralization test
60	ROC-AUC	receiver-operating-characteristics area under the curve

## 61 Background

62 SARS-CoV-2 antibody testing played and still plays an essential role in the management of the  
63 COVID-19 pandemic (1). Detection of specific antibodies following SARS-CoV-2 infection is  
64 important at both the individual and population levels to identify those at risk of infection (2).  
65 However, now in the early vaccination era of the COVID-19 pandemic, another essential role of  
66 SARS-CoV-2 serology is added: the determination of specific antibodies after active  
67 immunization (3, 4). Although this new role has not yet been finally defined, it is already clear  
68 that antibody assays will be needed for both vaccine development and approval process and the  
69 follow-up of vaccinated individuals. Licensing studies on a scale such as Pfizer/BioNtech and  
70 Moderna vaccines will not be feasible for all vaccine candidates and the companies behind them  
71 (5). For this reason, correlates of vaccine-induced protection will have to replace, at least in part,  
72 the measurement of clinical outcomes as the sole measure. For reasons of simplicity, relatively  
73 good standardizability, and broad applicability, SARS-CoV-2 antibody tests have the best chance  
74 of becoming such substitute endpoints (6).

75 The first SARS-CoV-2 antibody testing systems were designed to distinguish individuals with  
76 prior COVID-19 infection from those who were still naive to this new virus (7). Therefore, these  
77 immunoassays were usually developed as qualitative rather than quantitative tests and were  
78 designed by the manufacturer to achieve the highest possible specificity and high sensitivity.  
79 High specificity was indispensable, especially at the beginning of the pandemic, because the  
80 extremely low seroprevalence rates led to many false positives and low positive predictive values  
81 even with tests having a specificity of 99% (8). In contrast, the sensitivity of SARS-CoV-2  
82 testing was often reduced to assure the high specificities needed for these assays (9). The lower

83 antibody levels further aggravated suboptimal sensitivities in mild/asymptomatic infections and  
84 during the pandemic by the natural decline in antibody levels (10-15).

85 Various antigens have been used for this purpose, but essentially two types can be distinguished:  
86 nucleocapsid- and spike protein-based assays (16). Antibodies directed against SARS-CoV-2  
87 specific nucleocapsid (NC) antigens are induced early and strongly in most infected individuals  
88 due to the virus nucleocapsid's typical strong immunogenicity (17). Furthermore, a very high  
89 specificity can be achieved by targeted modification of the nucleocapsid antigen so that no cross-  
90 reactivity is observed even with closely related viruses. The discriminatory properties of such  
91 nucleocapsid-based antibody assays can therefore be excellent (18, 19). The physiological  
92 significance of these antibodies, on the other hand, is unclear, and these surrogate markers for a  
93 previous infection are unlikely to be functionally relevant to confer protection or immunity. The  
94 antibodies that react with the spike protein (S), however, act differently. At least a proportion of  
95 these S-binding antibodies are likely to have the function of neutralizing antibodies (20). Thus, it  
96 is not surprising that numerous studies have shown a correlation between spike protein binding  
97 assays and various forms of functional virus neutralization assays (21-26).

98 In the context of SARS-CoV-2 vaccines, it is precisely these neutralizing antibodies that are of  
99 paramount importance. The primary goal of active immunization is to induce many SARS-CoV-  
100 2-specific neutralizing antibodies that ideally prevent the pathogen's entry and thus infection or  
101 stop the systemic spread to prevent disease (27). The functional virus neutralization assays are  
102 not feasible everywhere: assays with live viruses require biosafety level 3, but variants such as  
103 pseudotyped neutralization assays are also labor-intensive and cannot be performed at high  
104 throughput (28-30). Classical antibody assays, which measure the reactivity of antibodies in

105 serum/plasma with defined antigens, can be performed very rapidly and in high throughput, in  
106 contrast to neutralization tests.

107 Thus, anti-spike protein assays will play an important role in vaccine development, licensing, and  
108 efficacy monitoring in the future. However, these test systems must be able to reliably quantitate  
109 SARS-CoV-2 specific antibody levels, be comparable to each other, and have good to excellent  
110 agreement with the presence of neutralizing antibodies. The comparability of antibody assays is  
111 expected to be improved by the recent introduction of a first WHO International Standard for  
112 anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/136) with reference to neutralizing  
113 antibodies.

114 In the present work, we aim to go a step further and characterize the vaccination response after  
115 the first administration of the Pfizer/BioNTech bnt162b2 vaccine using five commercial  
116 quantitative anti-spike protein antibody assays (4 of them with manufacturer's correction factor  
117 for the WHO standard) in a head-to-head comparison.

## 118 **Methods**

### 119 **Study design and participants**

120 This prospective observational study includes sera taken from 69 individuals without a previous  
121 SARS-CoV-2 infection taken  $21 \pm 1$  days (mean  $\pm$  standard deviation) after the first dose of the  
122 Pfizer/BioNTech BNT162b2 vaccine. Further inclusion criteria were an age  $>18$  years, whereas  
123 an insufficient amount of serum would have led to exclusion from the study. The study protocol  
124 was reviewed and approved by the Ethics Committee of the Medical University of Vienna  
125 (EK1066/2021). All participants provided written informed consent to donate blood for the  
126 evaluation of diagnostic test systems (EK404/2012).

## 127 Laboratory procedures

128 Serum was obtained and stored at 2 – 10°C for <7 days within the MedUni Wien Biobank, a  
129 centralized facility for the preparation and storage of biomaterial with certified quality  
130 management (ISO 9001:2015)(31). All analytical procedures were performed at the Department  
131 for Laboratory Medicine, Medical University of Vienna. The following CE-marked binding  
132 assays were applied:

133 The Roche Elecsys® Anti-SARS-CoV-2 S (Roche S tAb) is an electrochemiluminescence  
134 sandwich immunoassay (ECLIA) and detects total antibodies directed against the receptor-  
135 binding domain (RBD) of the viral spike (S)-protein and was measured on cobas® e801 modular  
136 analyzers (Roche Diagnostics, Rotkreuz, Switzerland). The quantification range is between 0.4  
137 and 2500.0 U/mL. The manufacturer states intra- and interassay precision between 1 and 3%, a  
138 clinical specificity of 99.98% (99.91 – 100), and a cumulative sensitivity  $\geq 14$  days after the first  
139 positive PCR of 98.8% (98.1 – 99.3) if 0.8 U/mL is used as a cut-off.

140 The Abbott SARS-CoV-2 IgG II Quant-test (Abbott S IgG) is a chemiluminescence microparticle  
141 immunoassay (CMIA). It quantifies IgG-type antibodies against the RBD of the viral S-protein  
142 on an Abbott ARCHITECT platform (Abbott, Abbott Park, USA) between 21.0 and 40,000.0  
143 AU/mL. Intra- and interassay precision ranges between 3 and 5%. According to the  
144 manufacturer, clinical specificity is 99.55% (99.15 – 99.76), and clinical sensitivity is 98.81%  
145 (93.56 – 99.94)  $\geq 15$  days after the first positive PCR at a cut-off of  $\geq 50$  AU/mL.

146 The DiaSorin LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin TriS IgG) chemiluminescence  
147 immunoassay (CLIA) quantifies IgG antibodies against a trimeric S-protein antigen on a  
148 DiaSorin LIAISON (DiaSorin, Stillwater, USA). The quantification range is between 1.63 and  
149 800 AU/mL. Intra- and interassay precision ranges between 0 and 5%. According to the

150 manufacturer, clinical specificity is 99.5% (99.0 – 99.7), and clinical sensitivity  $\geq 15$  days after  
151 the first positive PCR is 98.7% (94.5 – 99.6) at a cut-off of  $\geq 13$  AU/mL.

152 The DiaSorin LIAISON SARS-CoV-2 S1/2 CLIA (DiaSorin S1/2 IgG) detects IgG antibodies  
153 against an S1/S2 combination antigen on a DiaSorin LIAISON (DiaSorin, Stillwater, USA). The  
154 quantification range is between 3.8 and 400.0 AU/mL. Intra- and interassay precision ranges  
155 between 0 and 4% and, according to the manufacturer, specificity among blood donors is 98.5%  
156 (97.5–99.2) and sensitivity is 97.4%  $>15$  days after diagnosis at a cut-off of  $>15$  AU/mL, whereby  
157 results between 12.0 and 15.0 AU/mL are considered borderline.

158 The Virion\Serion ELISA (enzyme-linked immunosorbent assay) agile SARS-CoV-2 IgG (Serion  
159 IgG) (Institut Virion-Serion, Wuerzburg, Germany) was analyzed on a FilterMax F5 Multiplate  
160 Reader (Molecular Devices, San José, USA) and quantifies IgG antibodies against total S-protein  
161 between 3 and 250 U/mL. Intra- and interassay precision ranges between 1 and 4%. According to  
162 the manufacturer, specificity is 99.2%, and sensitivity is 96.2% at a cut-off of 15 U/mL, with  
163 values between 10 and 15 U/mL being considered borderline results.

164 If applicable, binding antibody units per milliliter (BAU/mL), which are traceable to the WHO  
165 International Standard for anti-SARS-CoV-2 immunoglobulin, were calculated by applying the  
166 following conversion factors, as suggested by the manufacturers: Roche S tAb =  $\frac{U}{mL} * 1$ , Abbott S

167 IgG: =  $\frac{U}{mL} * \frac{1}{7}$ , DiaSorin TriS IgG =  $\frac{AU}{mL} * 2.6$ , Serion IgG =  $\frac{U}{mL} * 2.1$ .

168 We excluded prior SARS-CoV-2 infection by using the Roche Elecsys® SARS-CoV-2 ECLIA  
169 on the cobas® e801 analyzer (Roche), which detects total antibodies to the viral nucleocapsid  
170 antigen. These antibodies are not induced by vaccination with bnt162b2. This assay yields high  
171 diagnostic sensitivity (90%) and specificity (99.7%) for infections that occurred at least 14 days

172 before blood withdrawal (7). As suggested by the manufacturer, results >1.000 COI were  
173 considered positive.

174 Neutralizing capacity was estimated by performing a surrogate virus neutralization test (sVNT)  
175 (GenScript, Piscataway, USA). The assay was read on a Filtermax F5 multimodal plate reader.  
176 According to the manufacturer, it shows excellent positive (100% [87.1 – 100.0]) and negative  
177 percent agreement (100.0% [95.8 – 100.0]) with conventional plaque-reduction neutralization  
178 tests (PRNT<sub>50</sub> and PRNT<sub>90</sub>). Results  $\geq 30\%$  are considered positive.

## 179 Statistical analysis

180 Continuous data are given as a median and interquartile range, categorical data as counts and  
181 percentages. Passing-Bablok regressions, Cohen's Kappa (linear weights) and Spearman rank  
182 correlations evaluated the agreement between binding assays. The relationship between binding  
183 assays and results from the sVNT was described by quadratic curve fitting. The predictive value  
184 of binding assays regarding positivity in the sVNT was assessed by interpreting and comparing  
185 (according to DeLong) the areas under the curve (AUC) from receiver-operating-characteristics  
186 (ROC)-curves. Statistical significance was assumed if *P* values were below 0.05. All analyses  
187 were performed using MedCalc 19.6 (MedCalc, Ostend, Belgium), and graphs were drawn using  
188 GraphPad 9 (GraphPad, La Jolla, USA).

## 189 Results

### 190 Measurement ranges differ between binding assays

191 29 female (42%) and 40 male (58%) participants with a median age of 42 years (29 – 51) were  
192 included. Results from the five different antibody binding assays are presented in Table 1 and  
193 Figure 1. The Abbott S IgG assay showed the highest values with a median of 1097.1 AU/mL

194 (580.1 – 1959.5) and the broadest range (1.4 – 8281.0). In contrast, the DiaSorin S1/2 IgG CLIA  
195 yielded the lowest values (63.7 AU/mL [47.8 – 87.5]), and the levels ranged from below the limit  
196 of quantification (<3.8%, 1 sample) to 148.0. Two assays, the DiaSorin Tris IgG (195.0 AU/mL  
197 [99.0 – 337.3]) and the Serion IgG (50 U/mL [30 – 89]) returned a result above the measuring  
198 range for the same donor (>800 AU/mL and >250 U/mL). However, both tests used their full  
199 available range (lowest values: 1.8 AU/mL and <3 U/mL). Roche S tAb ECLIA results came in  
200 between the other test systems (79.6 U/mL [24.7 – 142.3]), ranging from 0.4 to 508.0.

201 The measured values indicate that the numerical results are strongly dependent on the test system  
202 used. In the next step, we aimed to evaluate the overall agreement between the test systems.

### 203 [Agreement between results from different binding assays](#)

204 Results from the Roche S tAb assay correlated well with those of the other binding assays  
205 (Abbott S IgG  $\rho=0.88$ , DiaSorin TriS IgG  $\rho=0.83$ , DiaSorin S1/2 IgG  $\rho=0.80$ , Serion IgG  
206  $\rho=0.82$ ). However, Passing-Bablok regression revealed relevant systematic and proportional  
207 differences: Abbott S IgG =  $82.5 + 15.54 * X$ , DiaSorin TriS IgG =  $33.4 + 2.18 * X$ , DiaSorin S1/2  
208 IgG =  $39.6 + 0.32 * X$ , Serion IgG =  $12.3 + 0.65 * X$ .

209 The Abbott S IgG assay correlated at  $\rho=0.90$  with the remaining three test systems (DiaSorin  
210 TriS IgG and S1/2 IgG, Serion IgG). In Passing-Bablok regression, all systematic and  
211 proportional errors were statistically significant: DiaSorin TriS IgG =  $24.5 + 0.13 * X$ , DiaSorin  
212 S1/2 IgG =  $34.5 + 0.02 * X$ , Serion IgG =  $6.2 + 0.04 * X$ .

213 The DiaSorin TriS IgG assay showed an excellent correlation with the remaining two tests  
214 (DiaSorin S1/2 IgG  $\rho=0.91$ , Serion IgG 0.94). In the Passing-Bablok regression, nevertheless,

215 marked deviations became apparent: DiaSorin S1/2 IgG =  $30.5 + 0.16 \cdot X$ , Serion IgG =  $-0.0 +$   
216  $0.31 \cdot X$ .

217 Finally, the DiaSorin S1/2 IgG and the Serion IgG correlated at  $\rho=0.91$ , and the Passing-Bablok  
218 regression equation was Serion IgG =  $-50.9 + 1.78 \cdot X$ . All described relationships, as well as  
219 related residual plots, are presented in Figure 2.

220 Furthermore, we assessed whether the classification of results into tertiles (0 – 33.3%, 33.4 –  
221 66.7%, 66.8 – 100%) was comparable, e.g., whether a sample yielding a result in the lowest  
222 tertile of test A was also in the lowest tertile of test B. Cohen's kappa was between 0.60 and 0.80,  
223 indicating a good agreement, for all but for one of the ten test combinations (Roche S tAb/Serion,  
224 kappa = 0.59, see Table 2).

225 In conclusion, the results of the investigated test systems correlate well but are not necessarily  
226 interchangeable. Several manufacturers provided conversion factors related to the WHO  
227 International Standard for SARS-CoV-2 immunoglobulin, as described in the methods section.  
228 Next, we wanted to clarify whether comparing converted BAU/mL instead of arbitrary values  
229 facilitates comparability.

### 230 [Associations between standardized binding assay results](#)

231 Binding antibody units per milliliter (BAU/mL) were calculated for the Abbott S IgG, the  
232 DiaSorin TriS IgG, and the Serion IgG, according to the recently proposed conversion factors.  
233 Results from the Roche S tAb ECLIA did not require conversion as indicated by the  
234 manufacturer.

235 As shown in Figure 3, the BAU/mL recalculation did not solve the problem of high proportional  
236 errors. The least proportional error could be observed for the relationship between Roche S tAb

237 and Serion IgG. However, the same combination was characterized by comparatively high  
238 variability ( $\rho=0.82$ ).

### 239 Correlation of binding assay results with a surrogate neutralization assay

240 In a final step, the binding assays' results were compared to percent inhibition of a surrogate virus  
241 neutralization assay (sVNT). In the sVNT, the tested samples yielded median values of 63% (50  
242 – 76), ranging from 6 to 92%. Figure 4a illustrates that all binding assays except the DiaSorin  
243 S1/2 IgG showed a quadratic relationship with the sVNT. The binding assays also differentiated  
244 those values clustered in the upper range of the sVNT. However, for the DiaSorin S1/2, the  
245 quadratic curve approached a straight line, indicating a mostly linear relationship between this  
246 binding assay and the sVNT within the observed range.

247 7 (10%) of the individuals yielded sVNT results below 30% inhibition, which is considered  
248 negative according to the manufacturer (Figure 1). Binding assay results were compared between  
249 positives and negatives in the sVNT by ROC-curve analysis. The resulting AUCs ranged between  
250 0.84 and 0.93 (see Figure 4b), however, the differences between AUCs were not statistically  
251 significant. Optimal cut-offs according to Youden's Index, as well as other cut-offs observed  
252 from the data and their respective sensitivities and specificities are given in Supplemental Table  
253 1. For three out of the five assays (Abbott S IgG, DiaSorin S1/2 IgG, and Serion IgG), all  
254 samples with a negative sVNT result could be correctly identified with a corresponding  
255 sensitivity of approximately 60%.

## 256 Discussion

257 SARS-CoV-2 antibody assays become important tools to evaluate the proportion of people  
258 affected by COVID-19 and identify those who are still at infection risk. Now with the first

259 vaccines available a new field of use for SARS-CoV-2 antibody tests will open up. First, many  
260 vaccinated individuals will be interested in confirming their own vaccination success based on  
261 the detection of specific antibodies. Second, vaccination-induced antibodies may be used as  
262 surrogate from which a protection correlate will be estimated. To date, only limited information  
263 on the performance of quantitative SARS-CoV-2 antibody assays is available, since most  
264 currently evaluated assays were developed in-house, as recently summarized by the CDC  
265 COVID-19 response group (32). Only for a few commercially available quantitative CE-marked  
266 test systems preliminary data on the performance are given in the literature (19, 22, 33-35).

267 Although a protection correlate for immunity in SARS-CoV-2 has not been defined yet, it is  
268 useful to begin this important preliminary work now (6). Therefore, in the present work, we  
269 compared different commercial SARS-CoV-2 antibody assays with spike protein reactivity using  
270 a vaccination cohort to give a first insight into the comparability of these assays.

271 With regard to the numerical results, we were able to determine a broad distribution of the result  
272 values for each individual test system, so that these were presented on a logarithmic scale. This is  
273 in line with recently published reports, showing the antibody response after a single dose of  
274 BNT162b2 vaccine (3, 4). Interestingly, in agreement with a study involving >500 participants in  
275 an identical study setting, we observed very similar mean values for the measurements with the  
276 DiaSorin S1/S2 IgG: 66.3 AU/mL versus 68.6 AU/mL (3). Therefore, it is reasonable to assume  
277 that our cohort is representative despite the moderate number of participants. In addition, we  
278 were able to show that the results of the different test systems varied by a factor of up to more  
279 than 50. This leads to the initial conclusion that a direct comparability of the numerical results of  
280 different test systems is unlikely to be given across the range of individual findings. Differences  
281 also occurred with respect to measurement ranges, and upper measurement limits were exceeded

282 in 2 out of 5 systems (DiaSorin TriS IgG and Serion IgG), although the study cohort reflects the  
283 antibody response before the administration of the 2<sup>nd</sup> dose of Pfizer/BioNTech vaccine in SARS-  
284 CoV-2 naïve individuals. However, it must be mentioned that it is not yet known up to which  
285 level a differentiation of the obtained values is meaningful. A recently published paper shows that  
286 an anti-S post-vaccination titer of 61.8 AU/mL for the Abbott S IgG was associated with  
287 reinfection after a single dose of vaccination. Since this value is only just above the threshold for  
288 positivity for this specific assay (50 AU/mL) and in our cohort >95% of all observed values were  
289 far higher (5th percentile: 207.5 AU/mL), this finding is plausible and suggests vaccine failure  
290 due to very low antibody production. Alternatively, a reinfection might have been caused in these  
291 subjects by a virus variant where vaccination protection is mitigated. Nevertheless, it can be  
292 assumed that the average values of completely vaccinated persons are significantly higher than  
293 those in our collective and thus the upper measurement limits could frequently be exceeded in  
294 most assays. If clinically relevant, this could make additional dilution steps necessary, which are  
295 not yet taken into account by the manufacturers.

296 Despite the different levels of measurement, all systems showed good correlations with each  
297 other. When the measured values of the individual antibody tests were assigned to tertiles, good  
298 agreement was shown between the lowest third, the middle third and the highest third of the  
299 results. Thus, one individual with known immunosuppressive therapy consistently showed no  
300 formation of antibodies in all five antibody binding assays tested. With defined cut-offs for low  
301 or high vaccination titers of the different test systems, at least a partial transferability of a result  
302 from one to another test system may therefore be expected.

303 Such transferability of results could also be anticipated via referencing the antibody assays used  
304 to an international reference standard (32). Indeed, a first WHO international SARS-CoV-2

305 antibody standard with the valence of 1000 BAU/mL has recently become available. This  
306 standard was used by the manufacturers for four out of five of the assays studied. However, this  
307 standardization was not introduced during the establishment of the test system, but post-hoc as a  
308 reference material to define a conversion factor of their own units in BAU/mL. It is therefore not  
309 surprising that, this subsequent correction did not reduce the existing systematic deviations  
310 (Figure 2) between the different tests. Only the Roche S tAb and Serion IgG tests were able to  
311 approximate the equivalence line, although here a very wide scattering of values around the trend  
312 lines was observed.

313 The in vitro binding of infection-associated antibodies to pathogen-specific antigens in an  
314 antibody test are important markers to objectify a past infection or vaccination. However, these  
315 do not necessarily say anything about the function of these antibodies (1). In SARS-CoV-2  
316 vaccination, an important goal is to induce neutralizing antibodies that will prevent the virus from  
317 binding to the cellular receptor, the ACE2 receptor, via the surface spike protein (36, 37). Tests  
318 to neutralize live viruses can only be performed in very specialized laboratories and  
319 unfortunately, in the case of SARS-CoV-2, are not standardized, making comparability almost  
320 impossible. For this reason, we chose to use a well-characterized surrogate virus neutralization  
321 test (sVNT) as a functional reference (38-40). In this assay, a simple ELISA format is used to  
322 determine the inhibition of conjugated RBD protein by neutralizing antibodies to the plate-bound  
323 ACE2 receptor. The manufacturer suggests a threshold for positivity of 30% inhibition. For the  
324 Abbott S IgG, the DiaSorin S1/2 IgG, and the Serion IgG assay, all samples below this threshold  
325 were identified at a corresponding sensitivity of about 60%. The corresponding criteria were 3 –  
326 17 times higher than the respective assays' thresholds for positivity. This implies that the cut-off  
327 values given for the respective test systems are only valid for the diagnosis of a past infection, but

328 do not necessarily represent a threshold value for the presence of sufficient neutralizing activity.

329 For the Roche S tAb and the DiaSorin TriS IgG assays, a single outlier avoided reaching

330 maximum specificity before sensitivity dropped to 3 and 32%, respectively.

331 In conclusion, we found a good correlation between all evaluated assays, however, the values

332 from the different test systems were not interchangeable, even when converted to BAU/mL using

333 the WHO international standard for SARS-CoV-2 immunoglobulin. Furthermore, it should be

334 noted that the thresholds for positivity provided by the manufacturers are of diagnostic value and

335 are not indicative of sufficient inhibitory capacities.

## 336 Acknowledgments

337 We thank all sample donors for their valuable contribution. We further want to thank Miss

338 Manuela Repl, Miss Susanne Keim, Miss Martina Trella, Miss Borka Radovanovic-Petrova, Miss

339 Monika Martiny, Miss Jadwiga Konarski, Mr. Bernhard Haunold, Miss Maedeh Iravany, and

340 Miss Shohreh Lashgari for perfect technical and administrative assistance. Conflicts of Interest:

341 NP received a travel grant from DiaSorin. The Dept. of Laboratory Medicine received

342 compensations for advertisement on scientific symposia from Roche, DiaSorin and Abbott, and

343 holds a grant for evaluating an in-vitro diagnostic device from Roche. The GenScript sVNT test

344 kit and the Serion IgG kit were kindly provided by the respective supplier (medac GmbH and

345 DiaChrom), the Abbott S IgG kit and the DiaSorin TriS IgG kit were kindly provided by the

346 manufacturers. There was no additional funding received for the present work.

## 347 References

348 1. Krammer F, Simon V. Serology assays to manage covid-19. Science 2020;368:1060-1.

- 349 2. Alter G, Seder R. The power of antibody-based surveillance. *N Engl J Med* 2020;383:1782-4.
- 350 3. Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, Edelstein M. Impact  
351 of age, ethnicity, sex and prior infection status on immunogenicity following a single dose  
352 of the bnt162b2 mrna covid-19 vaccine: Real-world evidence from healthcare workers,  
353 israel, december 2020 to january 2021. *Euro Surveill* 2021;26.
- 354 4. Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, et al. Effect of previous sars-  
355 cov-2 infection on humoral and t-cell responses to single-dose bnt162b2 vaccine. *Lancet*  
356 2021.
- 357 5. Jin P, Li J, Pan H, Wu Y, Zhu F. Immunological surrogate endpoints of covid-2019 vaccines:  
358 The evidence we have versus the evidence we need. *Signal Transduction and Targeted*  
359 *Therapy* 2021;6:48.
- 360 6. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates  
361 of protection against sars-cov-2 in rhesus macaques. *Nature* 2020.
- 362 7. Perkmann T, Perkmann-Nagele N, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, et  
363 al. Side-by-side comparison of three fully automated sars-cov-2 antibody assays with a  
364 focus on specificity. *Clin Chem* 2020;66:1405-13.
- 365 8. Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda M, et al.  
366 Prevalence of sars-cov-2 in spain (ene-covid): A nationwide, population-based  
367 seroepidemiological study. *Lancet* 2020;396:535-44.
- 368 9. Oved K, Olmer L, Shemer-Avni Y, Wolf T, Supino-Rosin L, Prajgrod G, et al. Multi-center  
369 nationwide comparison of seven serology assays reveals a sars-cov-2 non-responding  
370 seronegative subpopulation. *EClinicalMedicine* 2020;29:100651.
- 371 10. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological  
372 assessment of asymptomatic sars-cov-2 infections. *Nat Med* 2020;26:1200-4.

- 373 11. Lumley SF, Wei J, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. The duration,  
374 dynamics and determinants of sars-cov-2 antibody responses in individual healthcare  
375 workers. *Clin Infect Dis* 2021.
- 376 12. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal  
377 analysis of serology and neutralizing antibody levels in covid19 convalescents. *J Infect*  
378 *Dis* 2020.
- 379 13. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent  
380 antibody responses to sars-cov-2 in convalescent individuals. *Nature* 2020;584:437-42.
- 381 14. Buss LF, Prete CA, Jr., Abraham CMM, Mendrone A, Jr., Salomon T, de Almeida-Neto C, et  
382 al. Three-quarters attack rate of sars-cov-2 in the brazilian amazon during a largely  
383 unmitigated epidemic. *Science* 2021;371:288-92.
- 384 15. Bolotin S, Tran V, Osman S, Brown KA, Buchan SA, Joh E, et al. Sars-cov-2 seroprevalence  
385 survey estimates are affected by anti-nucleocapsid antibody decline. *J Infect Dis* 2021.
- 386 16. Favresse J, Brauner J, Bodart N, Vigneron A, Roisin S, Melchionda S, et al. An original  
387 multiplex method to assess five different sars-cov-2 antibodies. *Clin Chem Lab Med*  
388 2020.
- 389 17. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. Sars-cov-2-specific  
390 t cell immunity in cases of covid-19 and sars, and uninfected controls. *Nature*  
391 2020;584:457-62.
- 392 18. Musico A, Frigerio R, Mussida A, Barzon L, Sinigaglia A, Riccetti S, et al. Sars-cov-2  
393 epitope mapping on microarrays highlights strong immune-response to n protein region.  
394 *Vaccines (Basel)* 2021;9.
- 395 19. Klausberger M, Dürkop M, Haslacher H, Wozniak-Knopp G, Cserjan-Puschmann M,  
396 Perkmann T, et al. A comprehensive antigen production and characterization study for

- 397 easy-to-implement, highly specific and quantitative sars-cov-2 antibody assays. medRxiv  
398 2021.
- 399 20. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust  
400 neutralizing antibodies to sars-cov-2 infection persist for months. *Science* 2020;370:1227-  
401 30.
- 402 21. Bal A, Pozzetto B, Trabaud MA, Escuret V, Rabilloud M, Langlois-Jacques C, et al.  
403 Evaluation of high-throughput sars-cov-2 serological assays in a longitudinal cohort of  
404 patients with mild covid-19: Clinical sensitivity, specificity and association with virus  
405 neutralization test. *Clin Chem* 2021.
- 406 22. Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, et al. Clinical and  
407 analytical performance of an automated serological test that identifies s1/s2-neutralizing  
408 igg in covid-19 patients semiquantitatively. *J Clin Microbiol* 2020;58.
- 409 23. Padoan A, Bonfante F, Pagliari M, Bortolami A, Negrini D, Zuin S, et al. Analytical and  
410 clinical performances of five immunoassays for the detection of sars-cov-2 antibodies in  
411 comparison with neutralization activity. *EBioMedicine* 2020;62:103101.
- 412 24. Patel EU, Bloch EM, Clarke W, Hsieh YH, Boon D, Eby Y, et al. Comparative performance  
413 of five commercially available serologic assays to detect antibodies to sars-cov-2 and  
414 identify individuals with high neutralizing titers. *J Clin Microbiol* 2021;59.
- 415 25. Suhandynata RT, Hoffman MA, Huang D, Tran JT, Kelner MJ, Reed SL, et al. Commercial  
416 serology assays predict neutralization activity against sars-cov-2. *Clin Chem* 2020.
- 417 26. Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, et al. Association  
418 between sars-cov-2 neutralizing antibodies and commercial serological assays. *Clin Chem*  
419 2020.
- 420 27. Krammer F. Sars-cov-2 vaccines in development. *Nature* 2020;586:516-27.

- 421 28. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Establishment and validation of a pseudovirus  
422 neutralization assay for sars-cov-2. *Emerg Microbes Infect* 2020;9:680-6.
- 423 29. Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS, et al. Quantifying  
424 absolute neutralization titers against sars-cov-2 by a standardized virus neutralization  
425 assay allows for cross-cohort comparisons of covid-19 sera. *mBio* 2021;12.
- 426 30. Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E, et al.  
427 Development of a rapid focus reduction neutralization test assay for measuring sars-cov-2  
428 neutralizing antibodies. *Curr Protoc Immunol* 2020;131:e116.
- 429 31. Haslacher H, Gerner M, Hofer P, Jurkowitsch A, Hainfellner J, Kain R, et al. Usage data and  
430 scientific impact of the prospectively established fluid bioresources at the hospital-based  
431 meduni wien biobank. *Biopreserv Biobank* 2018;16:477-82.
- 432 32. Gundlapalli AV, Salerno RM, Brooks JT, Averhoff F, Petersen LR, McDonald LC, et al.  
433 Sars-cov-2 serologic assay needs for the next phase of the us covid-19 pandemic  
434 response. *Open Forum Infect Dis* 2021;8:ofaa555.
- 435 33. Schaffner A, Risch L, Aeschbacher S, Risch C, Weber MC, Thiel SL, et al. Characterization  
436 of a pan-immunoglobulin assay quantifying antibodies directed against the receptor  
437 binding domain of the sars-cov-2 s1-subunit of the spike protein: A population-based  
438 study. *J Clin Med* 2020;9.
- 439 34. Soleimani R, Khourssaji M, Gruson D, Rodriguez-Villalobos H, Berghmans M, Belkhir L, et  
440 al. Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative  
441 antibody measurements in covid-19 patients. *J Med Virol* 2021;93:1465-77.
- 442 35. Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-sars-cov-2 antibodies:  
443 Analytical and clinical evaluation. *J Clin Microbiol* 2021.

- 444 36. Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, et al. Molecular  
445 interaction and inhibition of sars-cov-2 binding to the ace2 receptor. *Nat Commun*  
446 2020;11:4541.
- 447 37. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of sars-  
448 cov-2 by full-length human ace2. *Science* 2020;367:1444-8.
- 449 38. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, et al. A simple  
450 protein-based surrogate neutralization assay for sars-cov-2. *JCI Insight* 2020;5.
- 451 39. Perera R, Ko R, Tsang OTY, Hui DSC, Kwan MYM, Brackman CJ, et al. Evaluation of a  
452 sars-cov-2 surrogate virus neutralization test for detection of antibody in human, canine,  
453 cat, and hamster sera. *J Clin Microbiol* 2021;59.
- 454 40. von Rhein C, Scholz T, Henss L, Kronstein-Wiedemann R, Schwarz T, Rodionov RN, et al.  
455 Comparison of potency assays to assess sars-cov-2 neutralizing antibody capacity in  
456 covid-19 convalescent plasma. *J Virol Methods* 2021;288:114031.

457

## 458 Legends to Figures

459 **Fig. 1:** Results from binding assays (A) and a surrogate virus neutralization test, sVNT (B). Solid  
460 lines mark the median. The dotted line in (B) marks the manufacturer's threshold for positivity  
461 (30%).

462 **Fig. 2:** Comparison of binding assays by linear regression (dotted lines indicate the 95%  
463 confidence interval) (A) and residual plots (B).

464 **Fig. 3:** Relationships between binding assay results and percent inhibition assayed using a  
465 surrogate virus neutralization test (threshold for positivity: 30%, dotted vertical lines). Presented  
466 are quadratic regression lines and their 95% confidence intervals.

467 **Fig. 4: (A)** Comparison of binding assay results converted to BAU/mL (binding antibody units  
468 per milliliter). Given are linear regression curves and their 95% confidence intervals. Dotted  
469 diagonal lines represent lines of equality. **(B)** ROC (receiver-operating-characteristics) curves of  
470 binding assays regarding the agreement with the results of a surrogate virus neutralization test  
471 (threshold for positivity: 30% inhibition).

472



473





















	Roche S tAb	Abbott S IgG	DiaSorin TriS IgG	DiaSorin S1/2 IgG	Serion IgG
<b>Median</b>	79.6	1097.1	195.0	63.7	50
<b>5<sup>th</sup> Percentile</b>	4.3	207.5	36.4	20.5	12
<b>25<sup>th</sup> Percentile</b>	24.7	580.1	99.0	47.8	30
<b>75<sup>th</sup> Percentile</b>	142.3	1959.5	337.3	87.5	89
<b>95<sup>th</sup> Percentile</b>	265	3812.4	545.3	105.2	169
<b>Mean</b>	96.4	1494.2	230.4	66.3	69
<b>Standard deviation</b>	92.9	1367.2	163.2	26.5	55
<b>Range</b>	0.4 – 508.0	1.4 – 8281.0	1.8 – >800.0	<3.8 – 148.0	2 - >250

**Tbl. 1:** Dimensions of position and spread for 5 S-protein based SARS-CoV-2 antibody assays calculated from N=69 samples taken 21±1 days after the first shot of bnt162b2.

	Abbott S IgG	DiaSorin TriS IgG	DiaSorin S1/2 IgG	Serion IgG
<b>Roche S tAb</b>	0.72±0.06	0.69±0.06	0.63±0.07	0.59±0.07
<b>Abbott S IgG</b>		0.64±0.07	0.74±0.06	0.64±0.07
<b>DiaSorin TriS IgG</b>			0.74±0.06	0.74±0.06
<b>DiaSorin S1/2 IgG</b>				0.80±0.05

**Tbl. 2:** Kappa ( $\pm 95\%$  confidence interval) for ten different test combinations regarding the classifications of samples into tertiles.






**A)****Abbott S****DiaSorin TriS****DiaSorin S1/2****Serion****Roche S****Abbott S****DiaSorin TriS****DiaSorin S1/2****B)****Abbott S****DiaSorin TriS****DiaSorin S1/2****Serion****Roche S****Abbott S****DiaSorin TriS****DiaSorin S1/2**

# Abbott S



# DiaSorin TriS

# Serion


Roche S








Abbott S



DiaSorin  
TriS



**A)****B)**